MDT Medtronic plc : Bullish and Bearish Analyst Opinions

When a caller asks about Medtronic, Cramer says, "I WOULD BUY MORE." The stock has pulled back to the high $80s, which he finds surprising given the company's positive execution. It is valued at 15 times earnings, which he considers "very inexpensive." The current level is a good opportunity to buy or average down, as the company is doing everything right. Continued broad market weakness could pressure the stock further despite its attractive valuation.

With the spin-off of the diabetes division, Metronic can now focus on its three remaining business... At these levels, I think the stock simply too cheap to ignore. Shedding the slow-growth diabetes unit removes a major drag on the company, allowing the market to finally recognize and properly value Medtronic's accelerating cardiovascular and med-surg businesses. LONG because it is a highly profitable, recession-proof medical device company trading at a cheap valuation (under 15x next year's earnings) with a solid 3.2% dividend yield. The remaining neuroscience division continues to decelerate, or the broader market ignores the value unlocked by the spin-off.

MiniMed, a diabetes management firm that will be separated from health-care giant Medtronic, raised $560 million in a US IPO that priced below its marketed range https://t.co/t4mjgVxRhX